Cancer cell therapy from Arcellx, Gilead shows promise in early data
Summary: The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti, although Wall Street analysts were divided on how the two drugs compare.
Sickle cell patient dies in Beam study of base editing therapy
Summary: Investigators judged the death to be related to busulfan, an old chemotherapy drug that’s used to prepare patients for infusion with CRISPR therapies like Beam’s.
Two former Alexion leaders fight through a tough market to sustain a rare disease biotech
Summary: Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech’s down market has made the company’s journey difficult.
VTR Biotech Unveils Upgraded National Technology and Innovation Center：A Leap Forward in Biotech Innovation
Summary: VTR Biotech announces the upgrade of its National Enterprise Technology Center. Founded in the early 1990s, the company has grown into a leading biotechnology innovator in China.
Vertex Tops Q3 Forecast on Strength of Cystic Fibrosis Sales, Raises Full-Year Revenue Guidance
Summary: Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid therapy suzetrigine in pain—both slated for January 2025.
